Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced the appointment of veteran biopharma leaders Yu Liu, M.D., Ph.D., MBA, as chief medical officer and Lynne Sullivan as chief financial officer.
Dr. Liu, who most recently served as vice president and head of early clinical development at Pfizer, will oversee Compass development of a deep pipeline of immuno-oncology and autoimmune disease candidates. The companys lead candidate, CTX-471, a fully human monoclonal antibody that induces remodeling of the tumor microenvironment and leads to immune-mediated destruction of solid tumors, is expected to enter the clinic in the first quarter of 2019. More than 15 therapeutic candidates are advancing through preclinical development and the research team continues to generate an exciting array of novel candidates through the companys proprietary antibody development platform.
Ms. Sullivan, who most recently served as senior vice president, finance at Biogen, will lead financial planning and management at Compass at a time of significant growth for the company.
Yu and Lynne bring essential skills and expertise to Compass as we prepare to take our lead program into the clinic in the coming months, said Thomas Schuetz, M.D., Ph.D., the companys co-founder and chief executive officer. Their depth of experience and the strength of their leadership will serve us well, and were excited to welcome them aboard.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
At Pfizer, Dr. Liu oversaw early clinical development of the companys pipeline candidates in internal medicine, rare disease and inflammation/immunology. Prior to Pfizer, Dr. Liu led Biogens early clinical development effort in rare disease, with an emphasis on cell and gene therapy. Earlier, he held various leadership roles at Bristol-Myers Squibb, culminating in his position as vice president of the oncology business unit, based in Shanghai, China. Previously Dr. Liu held positions at Essentialis Therapeutics and Amgen. Dr. Liu trained in internal medicine at Massachusetts General Hospital. He received his Ph.D. in immunology from Boston University and his MBA in finance from University of Massachusetts, Boston. He also completed a residency scholarship program in clinical research at the Harvard School of Public Health.
At Biogen, Ms. Sullivan moved through positions of increasing responsibility during her more than 10-year tenure and was named senior vice president of finance in 2015. In that role, she led financial planning and analysis, corporate finance and tax functions for Biogens global operations. Prior to Biogen, Ms. Sullivan served as a vice president overseeing tax function for Merck KGaAs North American operations and was Seronos Vice President, Tax, Americas and International for seven years. She was a tax partner in the Boston office of Arthur Andersen prior to joining Serono. She currently serves as director and chair of the audit committee for both resTORbio and Solid Biosciences. Ms. Sullivan earned a bachelors degree in accounting from Suffolk University and a masters in taxation from Bentley University. She is also a CPA in Massachusetts.
About Compass Therapeutics
Compass Therapeutics currently has more than 15 antibody, antibody combination and bispecific programs advancing through preclinical development, targeting multiple pathways of significance for the immune system. The companys offices and labs are based in Kendall Square in Cambridge, Mass. Compass currently has approximately 80 full-time employees.
Ten Bridge Communications